Hims & Hers Health, Inc. (NYSE:HIMS) Shares Sold by Quinn Opportunity Partners LLC

Quinn Opportunity Partners LLC trimmed its position in Hims & Hers Health, Inc. (NYSE:HIMS - Free Report) by 94.5% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 39,968 shares of the company's stock after selling 690,682 shares during the quarter. Quinn Opportunity Partners LLC's holdings in Hims & Hers Health were worth $966,000 at the end of the most recent quarter.

Other large investors also recently modified their holdings of the company. HighTower Advisors LLC purchased a new stake in Hims & Hers Health during the third quarter valued at about $207,000. State Street Corp boosted its holdings in Hims & Hers Health by 4.7% during the 3rd quarter. State Street Corp now owns 4,626,543 shares of the company's stock valued at $85,221,000 after acquiring an additional 206,078 shares during the period. MML Investors Services LLC purchased a new position in Hims & Hers Health in the 3rd quarter worth approximately $197,000. Barclays PLC lifted its position in Hims & Hers Health by 9.7% in the third quarter. Barclays PLC now owns 308,363 shares of the company's stock valued at $5,680,000 after purchasing an additional 27,231 shares during the last quarter. Finally, Geode Capital Management LLC boosted its stake in shares of Hims & Hers Health by 12.7% during the third quarter. Geode Capital Management LLC now owns 4,289,549 shares of the company's stock valued at $79,029,000 after purchasing an additional 482,177 shares during the period. 63.52% of the stock is currently owned by institutional investors.

Insider Activity

In related news, insider Soleil Boughton sold 54,153 shares of the firm's stock in a transaction dated Tuesday, January 21st. The shares were sold at an average price of $29.90, for a total transaction of $1,619,174.70. Following the completion of the sale, the insider now directly owns 165,650 shares in the company, valued at approximately $4,952,935. This trade represents a 24.64 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, COO Melissa Baird sold 33,337 shares of Hims & Hers Health stock in a transaction on Wednesday, April 9th. The shares were sold at an average price of $27.32, for a total value of $910,766.84. Following the completion of the sale, the chief operating officer now owns 805,083 shares in the company, valued at $21,994,867.56. This represents a 3.98 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 806,811 shares of company stock worth $30,999,332 in the last quarter. Corporate insiders own 17.71% of the company's stock.

Wall Street Analysts Forecast Growth

A number of analysts have recently weighed in on HIMS shares. Piper Sandler increased their target price on shares of Hims & Hers Health from $24.00 to $35.00 and gave the stock a "neutral" rating in a report on Tuesday, February 25th. BTIG Research initiated coverage on Hims & Hers Health in a report on Tuesday, January 7th. They set a "buy" rating and a $35.00 target price for the company. Leerink Partners raised their target price on shares of Hims & Hers Health from $24.00 to $40.00 and gave the stock a "market perform" rating in a research report on Tuesday, February 25th. Morgan Stanley downgraded shares of Hims & Hers Health from an "overweight" rating to an "equal weight" rating and increased their price target for the stock from $42.00 to $60.00 in a research note on Tuesday, February 18th. Finally, Truist Financial lowered their price objective on Hims & Hers Health from $39.00 to $33.00 and set a "hold" rating for the company in a research report on Thursday, April 10th. Two investment analysts have rated the stock with a sell rating, seven have issued a hold rating and five have assigned a buy rating to the stock. Based on data from MarketBeat.com, Hims & Hers Health currently has a consensus rating of "Hold" and a consensus target price of $38.25.

Hims & Hers Health Stock Performance

HIMS stock traded up $0.32 during midday trading on Thursday, reaching $27.27. The stock had a trading volume of 13,557,063 shares, compared to its average volume of 15,229,234. The firm has a fifty day simple moving average of $37.94 and a two-hundred day simple moving average of $30.50. The stock has a market cap of $6.06 billion, a PE ratio of 62.11 and a beta of 1.65. Hims & Hers Health, Inc. has a 52-week low of $11.20 and a 52-week high of $72.98.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last posted its quarterly earnings results on Monday, February 24th. The company reported $0.11 EPS for the quarter, beating the consensus estimate of $0.09 by $0.02. The company had revenue of $481.14 million for the quarter, compared to analyst estimates of $494.56 million. Hims & Hers Health had a net margin of 8.19% and a return on equity of 10.97%. On average, sell-side analysts predict that Hims & Hers Health, Inc. will post 0.29 EPS for the current fiscal year.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.